10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Johnson & Johnson (NYSE: JNJ) reported anemic overall sales growth in the first half of 2017. The big healthcare company even saw a decline in year-over-year earnings during the period. Perhaps the most surprising disappointment of all was that pharmaceutical segment revenue was flat compared with the first half of last year.
Does all of this portend dark days ahead for J&J? Not at all. In fact, the stock has risen faster than the S&P 500 so far this year. Why? Probably because smart investors recognize that the near-term future for Johnson & Johnson looks pretty bright. Here are 10 rock-solid reasons that's the case.
Image source: Getty Images.
Source: Fool.com
Merck & Co. Inc. Stock
€121.20
1.510%
The stock is one of the favorites of our community with 28 Buy predictions and 1 Sell predictions.
As a result the target price of 124 € shows a slightly positive potential of 2.31% compared to the current price of 121.2 € for Merck & Co. Inc..
